We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Open Trial of Miglitol in Type 1 Diabetic Patients With Insulin Treatment

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00213109
First Posted: September 21, 2005
Last Update Posted: September 21, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Sanwa Kagaku Kenkyusho Co., Ltd.
  Purpose
The purpose of this study is evaluate the clinical efficacy and safety of Miglitol in patients with Type1 Diabetes Mellitus treated with insulin.

Condition Intervention Phase
Type 1 Diabetes Mellitus Drug: Miglitol Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Sanwa Kagaku Kenkyusho Co., Ltd.:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type1 Diabetes
  • Criteria of postprandial glucose and HbA1c are met

Exclusion Criteria:

  • Type2 Diabetes
  • Patients with antidiabetic drugs
  • The other exclusion criteria are met
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00213109


Locations
Japan
Chiba, Japan
Fukuoka, Japan
Gifu, Japan
Ibaraki, Japan
Kanagawa, Japan
Kumamoto, Japan
Oita, Japan
Sponsors and Collaborators
Sanwa Kagaku Kenkyusho Co., Ltd.
Investigators
Study Director: Clinical Promotion Group Sanwa Kagaku Kenkyusho Co., Ltd.
  More Information

ClinicalTrials.gov Identifier: NCT00213109     History of Changes
Other Study ID Numbers: MG1006
First Submitted: September 13, 2005
First Posted: September 21, 2005
Last Update Posted: September 21, 2006
Last Verified: September 2006

Keywords provided by Sanwa Kagaku Kenkyusho Co., Ltd.:
alpha-glucosidase inhibitor,Insulin

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Miglitol
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Hypoglycemic Agents
Physiological Effects of Drugs
Glycoside Hydrolase Inhibitors


To Top